Literature DB >> 11903505

Isoniazid pharmacokinetics in children according to acetylator phenotype.

E Rey1, D Gendrel, J M Treluyer, A Tran, A Pariente-Khayat, P d'Athis, G Pons.   

Abstract

The pharmacokinetics of isoniazid (INH) was studied in children (0-196 months old) according to their acetylator phenotype, estimated from the metabolic acetyl INH/INH molar plasma concentration ratio (MR) measured 3 h after INH oral administration. There were 17 slow (MR < 0.48) and 17 fast acetylators (MR > or = 0.48). The mean apparent plasma clearance was significantly lower, the mean apparent volume of distribution higher and the half-life longer in the slow acetylator group (C1, 0.298 +/- 0.099 L/h/kg; Vd, 1.56 +/- 0.65 L/kg; t1/2, 3.88 +/- 01.89 h) than in the fast acetylator group (Cl, 0.528 +/- 0.234 L/h/kg; Vd, 1.06 +/- 0.45; t1/2, 1.64 +/- 1.1 h). The half-life decreased with age. An impaired isoniazid elimination was suggested in children less than three months old, which may be in favour of an individual dose adjustment in this population.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11903505     DOI: 10.1046/j.1472-8206.2001.00044.x

Source DB:  PubMed          Journal:  Fundam Clin Pharmacol        ISSN: 0767-3981            Impact factor:   2.748


  14 in total

1.  In silico children and the glass mouse model: clinical trial simulations to identify and individualize optimal isoniazid doses in children with tuberculosis.

Authors:  Prakash M Jeena; William R Bishai; Jotam G Pasipanodya; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2010-11-22       Impact factor: 5.191

2.  Unified pharmacogenetics-based parent-metabolite pharmacokinetic model incorporating acetylation polymorphism for talampanel in humans.

Authors:  Peter Buchwald; Attila Juhász; Cynthia Bell; Márta Pátfalusi; John Howes; Nicholas Bodor
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-08       Impact factor: 2.745

Review 3.  Pharmacokinetics of First-Line Anti-Tubercular Drugs.

Authors:  Aparna Mukherjee; Rakesh Lodha; S K Kabra
Journal:  Indian J Pediatr       Date:  2019-03-26       Impact factor: 1.967

4.  Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations.

Authors:  S Thee; J A Seddon; P R Donald; H I Seifart; C J Werely; A C Hesseling; B Rosenkranz; S Roll; K Magdorf; H S Schaaf
Journal:  Antimicrob Agents Chemother       Date:  2011-10-03       Impact factor: 5.191

5.  Isoniazid pharmacokinetics in children treated for respiratory tuberculosis.

Authors:  H S Schaaf; D P Parkin; H I Seifart; C J Werely; P B Hesseling; P D van Helden; J S Maritz; P R Donald
Journal:  Arch Dis Child       Date:  2005-06       Impact factor: 3.791

6.  The pharmacogenetics of NAT2 enzyme maturation in perinatally HIV exposed infants receiving isoniazid.

Authors:  Rui Zhu; Jennifer J Kiser; Heiner I Seifart; Cedric J Werely; Charles D Mitchell; David Z D'Argenio; Courtney V Fletcher
Journal:  J Clin Pharmacol       Date:  2011-05-10       Impact factor: 3.126

7.  Isoniazid pharmacokinetics, pharmacodynamics, and dosing in South African infants.

Authors:  Jennifer J Kiser; Rui Zhu; David Z DʼArgenio; Mark F Cotton; Raziya Bobat; George D McSherry; Shabir A Madhi; Vincent J Carey; Heiner I Seifart; Cedric J Werely; Courtney V Fletcher
Journal:  Ther Drug Monit       Date:  2012-08       Impact factor: 3.681

8.  Influence of NAT2 Genotype and Maturation on Isoniazid Exposure in Low-Birth-Weight and Preterm Infants With or Without Human Immunodeficiency Virus (HIV) Exposure.

Authors:  Agathe Béranger; Adrie Bekker; Belén P Solans; Mark F Cotton; Mark Mirochnick; Avy Violari; Jiajia Wang; Mae Cababasay; Lubbe Wiesner; Renee Browning; Jack Moye; Edmund V Capparelli; Radojka M Savic
Journal:  Clin Infect Dis       Date:  2022-09-29       Impact factor: 20.999

9.  Reduced activities of cytochrome P450 1A2 and xanthine oxidase in children with growth hormone deficiency.

Authors:  M J Kennedy; D A Davis; N Smith; A Gaedigk; R E Pearce; G L Kearns
Journal:  Clin Pharmacol Ther       Date:  2008-10-08       Impact factor: 6.875

10.  Pharmacokinetics of isoniazid in low-birth-weight and premature infants.

Authors:  A Bekker; H S Schaaf; H I Seifart; H R Draper; C J Werely; M F Cotton; A C Hesseling
Journal:  Antimicrob Agents Chemother       Date:  2014-02-03       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.